Vestal Point Capital LP Purchases Shares of 400,000 UroGen Pharma Ltd. (NASDAQ:URGN)

Vestal Point Capital LP acquired a new position in UroGen Pharma Ltd. (NASDAQ:URGN) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 400,000 shares of the company’s stock, valued at approximately $5,080,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Point72 Asset Management L.P. increased its holdings in UroGen Pharma by 120.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after buying an additional 1,337,257 shares during the period. Millennium Management LLC increased its stake in shares of UroGen Pharma by 2,672.0% in the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock worth $19,480,000 after acquiring an additional 1,119,019 shares during the period. Cowen AND Company LLC boosted its holdings in UroGen Pharma by 29.1% in the second quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company’s stock valued at $35,229,000 after purchasing an additional 472,893 shares during the last quarter. Great Point Partners LLC grew its position in UroGen Pharma by 10.9% during the 2nd quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock worth $48,767,000 after purchasing an additional 285,714 shares during the period. Finally, Stonepine Capital Management LLC acquired a new position in shares of UroGen Pharma in the 3rd quarter valued at about $3,560,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Wall Street Analysts Forecast Growth

URGN has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Guggenheim assumed coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price target on the stock. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a research report on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I upgraded UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $48.38.

UroGen Pharma Stock Up 1.4 %

Shares of NASDAQ:URGN opened at $12.66 on Friday. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 1 year low of $10.60 and a 1 year high of $20.70. The business’s 50 day moving average price is $12.34 and its 200-day moving average price is $13.99.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the previous year, the firm posted ($0.68) earnings per share. On average, equities analysts anticipate that UroGen Pharma Ltd. will post -3.1 earnings per share for the current year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.